Betaloc Zoc, 50 mg 30 pcs

Indications

Active ingredient

Composition

How to take, the dosage

Betaloc® ZOC is intended to be taken once daily and is recommended to be taken in the morning. The Betaloc® ZOC tablet should be swallowed with fluids. Tablets (or tablets divided in half) should not be chewed or crumbled. Food intake does not affect the bioavailability of the drug.

The development of bradycardia should be avoided when adjusting the dose.

Arterial hypertension

50-100 mg once daily. If necessary, the dose may be increased to 200 mg daily or another antihypertensive agent may be added, preferably a diuretic and a dihydropyridine-type slow calcium channel blocker.

Stenocardia

100-200 mg of Betaloc® ZOC once daily. If necessary, another antianginal drug may be added to therapy.

Stable symptomatic chronic heart failure with impaired left ventricular systolic function

Patients must be in stable chronic heart failure without an episode of exacerbation within the past 6 weeks and without changes in underlying therapy within the past 2 weeks.

The therapy of heart failure with β-adrenoblockers may sometimes lead to a temporary worsening of the symptomatic picture. In some cases, continuation of therapy or reduction of the dose may be possible; in some cases it may be necessary to discontinue the drug.

Stable chronic heart failure, functional class II

The recommended starting dose of Betalock® ZOC for the first 2 weeks is 25 mg once daily. After 2 weeks of therapy, the dose may be increased to 50 mg once daily and may be doubled every 2 weeks thereafter.

The maintenance dose for long-term treatment is 200 mg of Betaloc® ZOC once daily.

Stable chronic heart failure, functional class III-IV The recommended starting dose for the first 2 weeks is 12.5 mg of Betaloc® ZOC (half tablet 25 mg) once daily. The dose is adjusted individually. During the period of dose increase the patient should be monitored, because in some patients the symptoms of heart failure may worsen.

After 1 to 2 weeks, the dose may be increased to 25 mg of Betaloc® ZOC once daily. Then, after 2 weeks, the dose may be increased to 50 mg once daily. In patients who tolerate the drug well the dose may be doubled every 2 weeks up to a maximum dose of 200 mg of Betaloc® ZOC once daily.

In cases of arterial hypotension and/or bradycardia, it may be necessary to reduce concomitant therapy or decrease the dose of Betaloc® ZOC. Arterial hypotension at the start of therapy does not necessarily indicate that a given dose of Betaloc® ZOC will not be tolerated with continued long-term treatment. However, the dose should not be increased until the condition has stabilized. Renal function may need to be monitored.

Heart rhythm disorders

100-200 mg of Betaloc® ZOC once daily. Supportive treatment after myocardial infarction 200 mg of Betaloc® ZOC once daily.

Functional cardiac disorders with tachycardia

100 mg of Betaloc® ZOC once daily. If necessary, the dose can be increased to 200 mg daily.

Prevention of migraine attacks

100-200 mg of Betaloc® ZOC once daily.

Renal dysfunction

There is no need to adjust the dose in patients with impaired renal function.

Hepatic dysfunction

Because of the low degree of binding to plasma proteins, no dose adjustment of metoprolol is usually required. However, in severe liver function impairment (in patients with severe cirrhosis or portocaval anastomosis), dose reduction may be required.

Elderly age

There is no need to adjust the dose in elderly patients.

Children

Limited experience with Betaloc® ZOC in children.

Interaction

Special Instructions

Synopsis

Contraindications

Side effects

Betaloc® ZOC is well tolerated by patients; side effects are mostly mild and reversible.

The following criteria were used to assess incidence: very common (>10%), common (1-9.9%), infrequent (0.1-0.9%), rare (0.01-0.09%), and very rare (<0.01%).

Cardiovascular System

Often: bradycardia, orthostatic hypotension (very rarely accompanied by syncope), coldness of extremities, palpitations;

Infrequent: Temporary worsening of heart failure symptoms, grade I AV block; cardiogenic shock in patients with acute myocardial infarction, edema, pain in the heart region;

Rare: other conduction disorders, arrhythmias;

Very rare: gangrene in patients with previous severe peripheral circulatory disturbances.

Central nervous system

Very common: increased fatigue; Frequent: dizziness, headache;

Infrequent: paresthesia, seizures, depression, decreased concentration, drowsiness or insomnia, nightmares;

Rare: increased nervous excitability, anxiety;

Very rare: amnesia/memory disturbances, depression, hallucinations.

Gastrointestinal tract

Often: nausea, abdominal pain, diarrhea, constipation; Infrequent: vomiting;

Rarely: dry oral mucosa.

Liver

Rarely: disorders of liver function; Very rare: hepatitis.

Skin

Infrequent: skin rash (similar to psoriasis-like urticaria), increased sweating;

Rare: Hair loss;

Very rare: photosensitization, exacerbation of psoriasis.

Respiratory organs

Often: shortness of breath on exercise; Infrequent: bronchospasm;

Rarely: rhinitis.

Sensory organs

Rarely: visual disturbances, dry and/or irritated eyes, conjunctivitis; Very rare: ringing in the ears, taste disturbances.

Skeletal and muscular system

Very rare: arthralgia.

Metabolism

Infrequent: weight gain.

blood

Very rare: thrombocytopenia.

Others

Rarely: impotence/sexual dysfunction.

Overdose

Pregnancy use

Similarities